▼Natalizumab for multiple sclerosis?
- 10 September 2008
- journal article
- review article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 46 (9), 69-72
- https://doi.org/10.1136/dtb.2008.09.0021
Abstract
Around 2.5 million people worldwide have multiple sclerosis, of whom about 85,000 are in the UK.1Natalizumab (pronounced na-ta-liz-you-mab; Tysabri - Biogen Idec), the first in a new class known as selective adhesion-molecule inhibitors, is licensed in the UK as monotherapy for "highly active" relapsing/remitting multiple sclerosis.2 Here we review natalizumab and assess its place for patients with multiple sclerosis.Keywords
This publication has 11 references indexed in Scilit:
- Disability as an outcome in MS clinical trialsNeurology, 2008
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Understanding monoclonal antibodiesDrug and Therapeutics Bulletin, 2007
- Reactivation of JC virus and development of PML in patients with multiple sclerosisNeurology, 2007
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Multiple sclerosisThe Lancet, 2002
- ▼Interferon beta-1a for multiple sclerosisDrug and Therapeutics Bulletin, 1998
- Interferon beta-1b - hope or hype?Drug and Therapeutics Bulletin, 1996
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989